A different picture can be seen in pediatric neuro-oncology, where the use of NGS is already recommended in clinical routine as BRAF inhibitors can be used for the treatment of BRAF-mutant higher-grade gliomas, alone or in combination with mitogen-activated protein kinase (MEK) inhibitors [5]. The gene discussed is MAP2K7; the disease is central nervous system cancer.